Molecular Pharmacology Unit, Department of Applied research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133, Milan, Italy.
Institut für Pharmazeutische und Medizinische Chemie, -Klinische Pharmazie, Westfälische Wilhelms-Universität Münster, 48149, Münster, Germany.
Cancer Chemother Pharmacol. 2018 Mar;81(3):427-441. doi: 10.1007/s00280-017-3502-7. Epub 2017 Dec 28.
An increasing number of manuscripts focus on the in vitro evaluation of established and novel anti-tumor agents in experimental models. Whilst the design of such in vitro assays is inherently flexible, some of these studies lack the minimum information necessary to critically evaluate their relevance or have been carried out under unsuitable conditions. The use of appropriate and robust methods and experimental design has important implications for generating results that are reliable, relevant, and reproducible. The Pharmacology and Molecular Mechanisms (PAMM) group of the European Organization for Research and Treatment of Cancer (EORTC) is the largest group of academic scientists working on drug development and bundle decades of expertise in this field. This position paper addresses all researchers with an interest in the preclinical and cellular pharmacology of anti-tumor agents and aims at generating basic recommendations for the correct use of compounds to be tested for anti-tumor activity using a range of preclinical cellular models of cancer.
越来越多的论文侧重于在实验模型中对已建立和新型抗肿瘤药物进行体外评估。虽然此类体外检测的设计具有内在的灵活性，但其中一些研究缺乏批判性评估其相关性所需的最低信息，或者是在不合适的条件下进行的。使用适当和稳健的方法和实验设计对于生成可靠、相关和可重复的结果具有重要意义。欧洲癌症研究与治疗组织（EORTC）的药理学和分子机制（PAMM）小组是从事药物开发的最大的学术科学家团体，拥有数十年在该领域的专业知识。本立场文件面向所有对抗肿瘤药物的临床前和细胞药理学感兴趣的研究人员，旨在为使用一系列临床前癌症细胞模型测试抗肿瘤活性的化合物的正确使用生成基本建议。
